Unlocking Opportunities in the Interstitial Lung Disease Market: 2025-2034 Forecast Report

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Will the Interstitial Lung Disease Industry Market Size Be by 2025?
The market size for interstitial lung disease has significantly expanded in the previous years. Expected to rise from a worth of $1.97 billion in 2024 to around $2.11 billion in 2025, it would be growing at a compound annual growth rate (CAGR) of about 7.2%. Elements contributing to growth during the historical period include increased awareness and advancements in diagnostic methodologies, modulation therapies for the immune system, programs for respiratory rehabilitation, and teams dedicated to multidisciplinary care.

What's the Long-Term Growth Forecast for the Interstitial Lung Disease Market Size Through 2029?
In the coming years, the market size for interstitial lung disease is predicted to witness robust expansion, reaching a valuation of $2.85 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. The predicted growth within this forecast period can be ascribed to elements such as precision medicine, the creation of innovative drugs, regenerative medicine, telehealth, and remote monitoring. Key trends expected during the forecast period are progress in imaging technology, the use of artificial intelligence in imaging, differentiation in fibrosis subtypes, and supportive care services.

View the full report here:
https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

What Are the Key Growth Drivers Fueling the Interstitial Lung Disease Market Expansion?
A surge in the occurrence of allergic conditions, where the immune system overly responds to a generally harmless allergen, is projected to spur the expansion of the interstitial lung disease market. These allergic conditions can often instigate the onset of interstitial lung disease (ILD), especially hypersensitivity pneumonitis. For instance, as per the National Asthma Council, an Australian non-profit aiming at advancing asthma care in November 2023, the number of asthma-related fatalities in 2022 was 467, out of which 299 were females and 168 were males. This marked an increase from the 355 deaths counted in 2021. The escalating prevalence of these allergic diseases is propelling the skin health foods market growth. Hence, the augmenting prevalence of allergic conditions is fueling the expansion of the interstitial lung disease market. It is also observed that a boost in the instances of autoimmune ailments is predicted to further drive the interstitial lung disease market. In autoimmune ailments, the body's immune system mistakenly targets the healthy tissues and cells. This rise in the occurrence of autoimmune ailments not only increases the demand for ILD-related healthcare facilities but also encourages research, development and advancements in patient care and therapies. For example, as per the projections by the Institute for Health Metrics and Evaluation, a US-based international health research center, in September 2023, the estimated number of rheumatoid arthritis cases globally might surge to 31.7 million by 2050. This estimate indicates a considerable hike in the cases over this period. Thus, the increasing cases of autoimmune ailments are propelling the growth of the interstitial lung disease market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13019&type=smp

What Are the Key Trends Driving Interstitial Lung Disease Market Growth?
Major companies active in the interstitial lung disease market are prioritizing trends like the introduction of innovative treatments for various interstitial lung diseases including idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive disease that scars lung tissue, leading to difficulties in breathing and decreased oxygen transfer. For example, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical company based in Germany, gained FDA approval for BI 1015550 Therapy for IPF treatment in February 2024. BI 1015550 is a novel oral treatment that blocks phosphodiesterase 4B (PDE4B), exhibiting anti-inflammatory and antifibrotic effects with the intent of slowing the decline in lung function in IPF.

How Is the Interstitial Lung Disease Market Segmented?
The interstitial lung disease market covered in this report is segmented -

1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs
2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis
3) By Application: Adults, Children
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil
3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib
4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13019&type=smp

Which Companies Are Leading the Charge in Interstitial Lung Disease Market Innovation?
Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.

Which Regions Are Leading the Global Interstitial Lung Disease Market in Revenue?
North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13019

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.